晚期霍奇金淋巴瘤应答调整治疗试验的长期随访
该研究分析了晚期霍奇金淋巴瘤成人患者应答调整治疗的长期结果,中位随访7.3年。对于iPET阴性患者,ABVD与AVD的3年PFS差异为1.3%(95% CI, -3.0至4.7),落在预设非劣效界值内。iPET阳性患者接受BEACOPP升级治疗,7年PFS为65.9%,7年OS为83.2%,第二恶性肿瘤累积发生率未增加。
要点
- iPET阴性患者省略博来霉素的降阶梯治疗非劣效于ABVD。
- iPET阳性患者升级至BEACOPP方案有效且安全。
- 7年第二恶性肿瘤累积发生率ABVD/AVD组为5.5%,BEACOPP组为2.5%。
核心结论
- 长期随访结果证实,iPET阴性后降阶梯治疗非劣效。
- iPET阳性患者接受BEACOPP升级治疗有效且安全,第二恶性肿瘤未增加。
研究设计与样本
- 应答调整治疗试验的长期随访分析,纳入成人晚期霍奇金淋巴瘤患者。
- 中位随访7.3年。
主要发现
- 所有患者7年无进展生存(PFS)为78.2%(95% CI, 75.6至80.5),7年总生存(OS)为91.6%(95% CI, 89.7至93.2)。
- ABVD与AVD的3年PFS差异为1.3%(95% CI, -3.0至4.7),落在预设非劣效界值内。
- 172例iPET阳性患者中,7年PFS为65.9%(95% CI, 58.1至72.6),7年OS为83.2%(95% CI, 76.2至88.3)。
- 7年第二恶性肿瘤累积发生率:接受ABVD/AVD者为5.5%(95% CI, 4.0至7.5),升级至BEACOPP者为2.5%(95% CI, 0.8至7.7)。
临床怎么用
- 对于iPET阴性的晚期霍奇金淋巴瘤成人患者,可考虑省略博来霉素的降阶梯治疗。
- 对于iPET阳性患者,可考虑升级至BEACOPP方案治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We analyzed long-term results of the response-adapted trial for adult patients with advanced-stage Hodgkin lymphoma. The aim was to confirm noninferiority of treatment de-escalation by omission of bleomycin from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for interim fluorodeoxyglucose positron emission tomography (iPET)-negative patients and assess efficacy and long-term safety for iPET-positive patients who underwent treatment intensification with escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP/BEACOPP14). The median follow-up is 7.3 years. For all patients, the 7-year progression-free survival (PFS) and overall survival (OS) are 78.2% (95% CI, 75.6 to 80.5) and 91.6% (95% CI, 89.7 to 93.2), respectively. The 1.3% difference in 3-year PFS (95% CI, -3.0 to 4.7) between ABVD and doxorubicin, vinblastine, and dacarbazine (AVD) now falls within the predefined noninferiority margin. Among 172 patients with positive iPET, the 7-year PFS was 65.9% (95% CI, 58.1 to 72.6) and the 7-year OS was 83.2% (95% CI, 76.2 to 88.3). The cumulative incidence of second malignancies at 7 years was 5.5% (95% CI, 4.0 to 7.5) for those receiving ABVD/AVD and 2.5% (95% CI, 0.8 to 7.7) for those escalated to BEACOPP. With extended follow-up, these results confirm noninferiority of treatment de-escalation after a negative iPET. Escalation with BEACOPP for iPET-positive patients is effective and safe, with no increase in second malignancies.
引用
- Luminari S, Fossa A, Trotman J, et al. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. J Clin Oncol. 2023. PMID: 37883739. doi:10.1200/JCO.23.01177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。